These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 18650162)

  • 1. A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37.
    Wapnir IL; Aebi S; Geyer CE; Zahrieh D; Gelber RD; Anderson SJ; Robidoux A; Bernhard J; Maibach R; Castiglione-Gertsch M; Coates AS; Piccart MJ; Clemons MJ; Costantino JP; Wolmark N; ; ;
    Clin Breast Cancer; 2008 Jun; 8(3):287-92. PubMed ID: 18650162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a prospective randomized trial evaluating chemotherapy after local therapy for isolated locoregional recurrences of breast cancer.
    Wapnir IL; Aebi S; Gelber S; Anderson SJ; Láng I; Robidoux A; Mamounas EP; Wolmark N
    Ann Surg Oncol; 2008 Nov; 15(11):3227-31. PubMed ID: 18784962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
    Overgaard M; Hansen PS; Overgaard J; Rose C; Andersson M; Bach F; Kjaer M; Gadeberg CC; Mouridsen HT; Jensen MB; Zedeler K
    N Engl J Med; 1997 Oct; 337(14):949-55. PubMed ID: 9395428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
    Pinto AC; Ades F; de Azambuja E; Piccart-Gebhart M
    Breast; 2013 Aug; 22 Suppl 2():S152-5. PubMed ID: 24074778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Negative margin status improves local control in conservatively managed breast cancer patients.
    Obedian E; Haffty BG
    Cancer J Sci Am; 2000; 6(1):28-33. PubMed ID: 10696736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer.
    Powles TJ; Hickish TF; Makris A; Ashley SE; O'Brien ME; Tidy VA; Casey S; Nash AG; Sacks N; Cosgrove D
    J Clin Oncol; 1995 Mar; 13(3):547-52. PubMed ID: 7884414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials.
    Taghian AG; Jeong JH; Mamounas EP; Parda DS; Deutsch M; Costantino JP; Wolmark N
    J Clin Oncol; 2006 Aug; 24(24):3927-32. PubMed ID: 16921044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.
    Ragaz J; Olivotto IA; Spinelli JJ; Phillips N; Jackson SM; Wilson KS; Knowling MA; Coppin CM; Weir L; Gelmon K; Le N; Durand R; Coldman AJ; Manji M
    J Natl Cancer Inst; 2005 Jan; 97(2):116-26. PubMed ID: 15657341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
    Pivot X; Romieu G; Debled M; Pierga JY; Kerbrat P; Bachelot T; Lortholary A; Espié M; Fumoleau P; Serin D; Jacquin JP; Jouannaud C; Rios M; Abadie-Lacourtoisie S; Tubiana-Mathieu N; Cany L; Catala S; Khayat D; Pauporté I; Kramar A;
    Lancet Oncol; 2013 Jul; 14(8):741-8. PubMed ID: 23764181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
    Baselga J; Perez EA; Pienkowski T; Bell R
    Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indications for breast-preserving surgery and adjuvant therapy in early breast cancer.
    Posner MC; Wolmark N
    Int Surg; 1994; 79(1):43-7. PubMed ID: 8063554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast conservation surgery achieving>or=2 mm tumor-free margins results in decreased local-regional recurrence rates.
    Kunos C; Latson L; Overmoyer B; Silverman P; Shenk R; Kinsella T; Lyons J
    Breast J; 2006; 12(1):28-36. PubMed ID: 16409584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
    Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
    J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of failure following surgical resection for malignant pleural mesothelioma.
    Jänne PA; Baldini EH
    Thorac Surg Clin; 2004 Nov; 14(4):567-73. PubMed ID: 15559064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 5-year results of a randomized trial of adjuvant radiation therapy after chemotherapy in breast cancer patients treated with mastectomy.
    Griem KL; Henderson IC; Gelman R; Ascoli D; Silver B; Recht A; Goodman RL; Hellman S; Harris JR
    J Clin Oncol; 1987 Oct; 5(10):1546-55. PubMed ID: 3309196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of local therapy on locoregional recurrence in postmenopausal women with breast cancer in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial.
    van Hezewijk M; Bastiaannet E; Putter H; Scholten AN; Liefers GJ; Rea D; Hasenburg A; Paridaens R; Hozumi Y; Markopoulos C; Seynaeve C; Jones SE; Marijnen CA; van de Velde CJ
    Radiother Oncol; 2013 Aug; 108(2):190-6. PubMed ID: 24044798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
    Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
    Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant therapy for breast cancer.
    NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials.
    Wapnir IL; Anderson SJ; Mamounas EP; Geyer CE; Jeong JH; Tan-Chiu E; Fisher B; Wolmark N
    J Clin Oncol; 2006 May; 24(13):2028-37. PubMed ID: 16648502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.